Company intelligence / Profile preview

Ellume

Brisbane, Queensland, Australia

Ownership: Private
Employees: ~1500
Development stage: Other

Overview

Ellume developed highly sensitive, digital, at-home diagnostic tests—most notably the first over-the-counter COVID-19 antigen test with FDA Emergency Use Authorization. The core platform also supported influenza and latent tuberculosis self-tests. Despite successful commercialization and contracts for mass production, Ellume went into administration in 2022 and was liquidated in 2023.

Therapeutic areas: Infectious Diseases
Modalities: DeviceDiagnostic device
Industry: Protein Biomarker Diagnostics

Partnerships

GlaxoSmithKline (consumer health distribution for flu diagnostics)QIAGEN (co-development of TB test, equity stake)US Department of Defense (manufacturing and supply contract)

Beyond the preview

Go deeper on Ellume.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ellume.

Explore the full profile